Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay C Strum

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Protocols in Pharmacology|February 2, 2012
Tissue expression profiling using real-time PCRJay C Strum, Kevin M Carrick, Joan S Stuart, et al.
Molecular Cancer Therapeutics|January 31, 2016
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced MyelosuppressionJohn E Bisi, Jessica A Sorrentino, Patrick J Roberts, et al.
Molecular Endocrinology (Baltimore, Md.)|October 13, 2009
MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1Jay C Strum, Jennifer H Johnson, James Ward, et al.
Journal of Alzheimer'S Disease : JAD|March 16, 2007
Rosiglitazone induces mitochondrial biogenesis in mouse brainJay C Strum, Ron Shehee, David Virley, et al.
Oncotarget|April 19, 2017
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumorsJohn E Bisi, Jessica A Sorrentino, Jamie L Jordan, et al.
Biochemical and Biophysical Research Communications|July 5, 2005
PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF ratsBaichun Yang, Peiyuan Lin, Kevin M Carrick, et al.
BMC Pharmacology|October 20, 2004
Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in ratsBaichun Yang, Kathleen K Brown, Lihong Chen, et al.
Diabetes|April 26, 2007
Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazoneJames X Rong, Yang Qiu, Michael K Hansen, et al.
Journal of the National Cancer Institute|February 4, 2012
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapyPatrick J Roberts, John E Bisi, Jay C Strum, et al.
Journal for Immunotherapy of Cancer|October 2, 2020
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapyAnne Y Lai, Jessica A Sorrentino, Konstantin H Dragnev, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Protocols in Pharmacology|February 2, 2012
Tissue expression profiling using real-time PCRJay C Strum, Kevin M Carrick, Joan S Stuart, et al.
Molecular Cancer Therapeutics|January 31, 2016
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced MyelosuppressionJohn E Bisi, Jessica A Sorrentino, Patrick J Roberts, et al.
Molecular Endocrinology (Baltimore, Md.)|October 13, 2009
MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1Jay C Strum, Jennifer H Johnson, James Ward, et al.
Journal of Alzheimer'S Disease : JAD|March 16, 2007
Rosiglitazone induces mitochondrial biogenesis in mouse brainJay C Strum, Ron Shehee, David Virley, et al.
Oncotarget|April 19, 2017
Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumorsJohn E Bisi, Jessica A Sorrentino, Jamie L Jordan, et al.
Biochemical and Biophysical Research Communications|July 5, 2005
PPARgamma agonists diminish serum VEGF elevation in diet-induced insulin resistant SD rats and ZDF ratsBaichun Yang, Peiyuan Lin, Kevin M Carrick, et al.
BMC Pharmacology|October 20, 2004
Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in ratsBaichun Yang, Kathleen K Brown, Lihong Chen, et al.
Diabetes|April 26, 2007
Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazoneJames X Rong, Yang Qiu, Michael K Hansen, et al.
Journal of the National Cancer Institute|February 4, 2012
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapyPatrick J Roberts, John E Bisi, Jay C Strum, et al.
Journal for Immunotherapy of Cancer|October 2, 2020
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapyAnne Y Lai, Jessica A Sorrentino, Konstantin H Dragnev, et al.
Pageof 2